View in EDS HTML Full Text PDF Full Text

A feedback mechanism from prostate cancer cells to macrophages, reinforced by STAT1, regulates tumor progression and resistance to radiotherapy.

Saved in:
Bibliographic Details
Title: A feedback mechanism from prostate cancer cells to macrophages, reinforced by STAT1, regulates tumor progression and resistance to radiotherapy.
Authors: Chen JY; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Xue YT; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Lin B; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Huang XY; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Lin F; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Chen DN; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Zhang WJ; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Wei Y; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Xue XY; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Fujian Key Laboratory of Tumor Immunotherapy, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Zheng QS; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Ke ZB; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. dr.urology@fjmu.edu.cn.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. dr.urology@fjmu.edu.cn., Xu N; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. drxun@fjmu.edu.cn.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. drxun@fjmu.edu.cn.; Fujian Key Laboratory of Tumor Immunotherapy, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. drxun@fjmu.edu.cn.
Source: Cell death & disease [Cell Death Dis] 2026 Mar 19; Vol. 17 (1). Date of Electronic Publication: 2026 Mar 19.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41856970
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A feedback mechanism from prostate cancer cells to macrophages, reinforced by STAT1, regulates tumor progression and resistance to radiotherapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chen+JY%22">Chen JY</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Xue+YT%22">Xue YT</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Lin+B%22">Lin B</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Huang+XY%22">Huang XY</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Lin+F%22">Lin F</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Chen+DN%22">Chen DN</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhang+WJ%22">Zhang WJ</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Wei+Y%22">Wei Y</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Xue+XY%22">Xue XY</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Fujian Key Laboratory of Tumor Immunotherapy, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Zheng+QS%22">Zheng QS</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Ke+ZB%22">Ke ZB</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. dr.urology@fjmu.edu.cn.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. dr.urology@fjmu.edu.cn.<br /><searchLink fieldCode="AU" term="%22Xu+N%22">Xu N</searchLink>; Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. drxun@fjmu.edu.cn.; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. drxun@fjmu.edu.cn.; Fujian Key Laboratory of Tumor Immunotherapy, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. drxun@fjmu.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101524092%22">Cell death & disease</searchLink> [Cell Death Dis] 2026 Mar 19; Vol. 17 (1). <i>Date of Electronic Publication: </i>2026 Mar 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101524092 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-4889 (Electronic) <i>NLM ISO Abbreviation: </i>Cell Death Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41856970
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41419-026-08577-5
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: A feedback mechanism from prostate cancer cells to macrophages, reinforced by STAT1, regulates tumor progression and resistance to radiotherapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chen JY
      – PersonEntity:
          Name:
            NameFull: Xue YT
      – PersonEntity:
          Name:
            NameFull: Lin B
      – PersonEntity:
          Name:
            NameFull: Huang XY
      – PersonEntity:
          Name:
            NameFull: Lin F
      – PersonEntity:
          Name:
            NameFull: Chen DN
      – PersonEntity:
          Name:
            NameFull: Zhang WJ
      – PersonEntity:
          Name:
            NameFull: Wei Y
      – PersonEntity:
          Name:
            NameFull: Xue XY
      – PersonEntity:
          Name:
            NameFull: Zheng QS
      – PersonEntity:
          Name:
            NameFull: Ke ZB
      – PersonEntity:
          Name:
            NameFull: Xu N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 19
              M: 03
              Text: 2026 Mar 19
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2041-4889
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cell death & disease
              Type: main
ResultId 1